Vericel (NASDAQ:VCEL) Stock: Insider Sean Flynn Sells 15,000 Shares

Vericel Corporation (NASDAQ:VCEL) insider Sean Flynn sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $51.92, for a total value of $778,800.00. Following the completion of the sale, the insider owned 1,990 shares in the company, valued at $103,320.80. The trade was a 88.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Vericel Stock Up 5.5%

VCEL stock opened at $54.62 on Friday. The business has a 50 day moving average of $41.01 and a 200 day moving average of $38.90. The firm has a market cap of $2.80 billion, a PE ratio of 85.35 and a beta of 1.08. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $55.60.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.21. The firm had revenue of $85.37 million for the quarter, compared to analysts’ expectations of $77.95 million. Vericel had a return on equity of 9.09% and a net margin of 10.27%. The company’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 earnings per share. On average, research analysts expect that Vericel Corporation will post 0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vericel

A number of large investors have recently added to or reduced their stakes in VCEL. Lisanti Capital Growth LLC bought a new stake in Vericel in the second quarter worth $5,356,000. Man Group plc purchased a new stake in Vericel during the second quarter valued at $2,998,000. Scholtz & Company LLC bought a new position in Vericel during the second quarter valued at $2,287,000. Bank of New York Mellon Corp bought a new position in Vericel during the second quarter valued at $12,366,000. Finally, Madison Asset Management LLC bought a new position in Vericel during the second quarter valued at $2,230,000.

Wall Street Analyst Weigh In

Several research analysts have issued reports on VCEL shares. HC Wainwright lifted their target price on shares of Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Friday. TD Cowen raised their price target on shares of Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a report on Thursday, July 30th. Truist Financial set a $65.00 price objective on shares of Vericel in a report on Friday. Finally, Wall Street Zen upgraded Vericel from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Vericel presently has an average rating of “Moderate Buy” and an average target price of $60.80.

Trending Headlines about Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.